Risk stratification by genetic mutation in dilated cardiomyopathy
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0004913
- Lead Sponsor
- Yonsei University Health System, Gangnam Severance Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
1) or 2) with 3)
1) Non-ischemic dilated cardiomyopathy with functional class II or more and persistently reduced left ventricular ejection fraction of 35% or less than 35% even after medical treatment at least 3 months. (regardless of ICD or CRT implantation)
2) Patients with dilated cardiomyopathy who underwent ICD implantation as a secondary prevention purpose and left ventricular ejection fraction less than 50% even after medical treatment.
3) Patients with age of 19 to 85 years who agree to study enrollment.
1) Patients with expected survival duration is within 6 months due to cancer or cerebrovascular disease.
2) Patients with dilated cardiomyopathy which related to neuromuscular disease
3) Patients who can't understand study purpose due to cognitive dysfunction or unstable hemodynamic status.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sudden cardiac death oradmission due to heart failure aggrevation or death due to heart failure aggrevation or cardiac transplatation or left ventricular assist device implantation due to progression to end-stage heart failure
- Secondary Outcome Measures
Name Time Method Appropriate anti-tachycardia pacing or appropriate ICD shock or ventricular tachycardia or ventricular fibrillation or new onset atrial fbrillation detected in EGM